secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000950170-24-021099
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics reports Q4 2023 net loss of $1.38/share; positive SEQUOIA-HCM results, NDA planned for Q3 2024
--------------------------------------------------------------------------------

- Net loss Q4 2023: $136.9M ($1.38/share); full year net loss $526.2M ($5.45/share).
- Year-end cash $655.4M; additional ~$83M raised via ATM in early 2024; ~2-year cash runway.
- SEQUOIA-HCM showed aficamten improved pVO2 by 1.74 mL/kg/min (p=0.000002) vs placebo; all 10 secondary endpoints met.
- Plans to submit NDA to FDA in Q3 2024 and MAA to EMA in Q4 2024 for aficamten.
- 2024 guidance: revenue $3-5M, operating expenses $420-450M, net cash utilization ~$390-420M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/0000950170-24-021099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024021099/cytk-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-021099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer